Silexion Therapeutics Corp. has announced significant preclinical research results for its lead RNA interference (RNAi) therapy, SIL204, targeting KRAS-driven cancers. The company reported that SIL204 demonstrated substantial tumor inhibition in human KRAS-mutated cancer cell line models, including pancreatic, colorectal, and lung cancers. These findings, achieved in 2025, have not yet been presented in human clinical trials, which are scheduled to begin in the first half of 2026. Silexion also completed regulatory toxicology studies and received positive feedback from Germany's Federal Institute for Drugs and Medical Devices (BfArM) on its Phase 2/3 trial design, paving the way for the upcoming clinical trial of SIL204 in locally advanced pancreatic cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001157833-en) on January 06, 2026, and is solely responsible for the information contained therein.